Amedisys Stock Forecast, Price & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 72.4% and is now trading at $293.89.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amedisys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Amedisys.

Amedisys, Inc. (NASDAQ:AMED) posted its quarterly earnings results on Monday, November, 2nd. The health services provider reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.25. The health services provider had revenue of $544.07 million for the quarter, compared to analyst estimates of $533.09 million. Amedisys had a return on equity of 26.41% and a net margin of 8.22%.
View Amedisys' earnings history.

Amedisys updated its FY20 earnings guidance on Wednesday, October, 28th. The company provided earnings per share guidance of $6.02-6.08 for the period, compared to the Thomson Reuters consensus estimate of $4.95. The company issued revenue guidance of $2.067-2.072 billion, compared to the consensus revenue estimate of $2.06 billion.

12 Wall Street analysts have issued 12 month price objectives for Amedisys' stock. Their forecasts range from $190.00 to $325.00. On average, they expect Amedisys' stock price to reach $263.69 in the next twelve months. This suggests that the stock has a possible downside of 10.3%.
View analysts' price targets for Amedisys or view Wall Street analyst' top-rated stocks.

Amedisys saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 534,100 shares, an increase of 40.4% from the December 15th total of 380,500 shares. Based on an average trading volume of 161,800 shares, the short-interest ratio is presently 3.3 days.
View Amedisys' Short Interest.

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), The Providence Service (PRSC), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all of AMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by many different retail and institutional investors. Top institutional shareholders include Gradient Investments LLC (0.06%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.02%), Crossmark Global Holdings Inc. (0.01%), HBW Advisory Services LLC (0.01%) and Contravisory Investment Management Inc. (0.00%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Gradient Investments LLC, State of Alaska Department of Revenue, and Contravisory Investment Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

AMED stock was bought by a variety of institutional investors in the last quarter, including HBW Advisory Services LLC, 6 Meridian, Crossmark Global Holdings Inc., and Louisiana State Employees Retirement System. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $293.89.

Amedisys has a market capitalization of $9.64 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]